Monday, January 9, 2017

Microbion Finds $25M For Treating Infections

Bozeman, Montana- and Vancouver, British Columbia-based Microbion Corporation, a developer of biopharmaceuticals aimed at treating hard to treat and antibiotic-resistant infections, has raised $25M in a funding round. The funding came from Quark Ventures and GF Securities. Microbion is developing a compound aimed at treating infections, by attacking both bacteria and related microbial biofilms. The funding will go towards completing a Phase 1B/2A study in treating diabetic foot ulcers.